Similar phase III trials, STR1VE-EU (NCT03461289) and STR1VE-AP (NCT03837184), aimed to assess the efficacy and safety of the treatment in SMA infants of similar age and SMN2 copy number. Here, SMN2 is linked to proximal spinal muscular atrophy.